CN113057298A - Composition with function of relieving asthenopia and preparation method thereof - Google Patents

Composition with function of relieving asthenopia and preparation method thereof Download PDF

Info

Publication number
CN113057298A
CN113057298A CN202010000833.3A CN202010000833A CN113057298A CN 113057298 A CN113057298 A CN 113057298A CN 202010000833 A CN202010000833 A CN 202010000833A CN 113057298 A CN113057298 A CN 113057298A
Authority
CN
China
Prior art keywords
parts
relieving
asthenopia
composition
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010000833.3A
Other languages
Chinese (zh)
Inventor
刘磊
任立焕
王鹤
秦玉霞
侯金才
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenwei Pharmaceutical Group Co Ltd
Original Assignee
Shenwei Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenwei Pharmaceutical Group Co Ltd filed Critical Shenwei Pharmaceutical Group Co Ltd
Priority to CN202010000833.3A priority Critical patent/CN113057298A/en
Publication of CN113057298A publication Critical patent/CN113057298A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the technical field of health-care food, and particularly discloses a composition with a function of relieving visual fatigue, health-care food and a preparation method thereof. The composition with the function of relieving the asthenopia comprises the following components in parts by weight: 5-40 parts of blueberry powder; 0.2-15 parts of cowberry concentrated powder; 0.1-10 parts of lutein; 0.1-10 parts of grape seed extract; 0.1-10 parts of vitamin mineral premix. The composition provided by the invention can increase action sites for relieving the asthenopia, realizes the combined action of multiple ways to achieve the aim of relieving the asthenopia, and ensures that the obtained composition has good effect of relieving the asthenopia.

Description

Composition with function of relieving asthenopia and preparation method thereof
Technical Field
The invention relates to the technical field of health-care food, in particular to a composition with a function of relieving visual fatigue, health-care food and a preparation method thereof.
Background
Asthenopia is a common ophthalmic disease, and dry eyes, sour eyes, blurred vision and even visual deterioration caused by asthenopia directly influence the work and life of people. The eyestrain is mainly caused by that when people concentrate on watching screens of electronic products such as televisions, computers or mobile phones and the like at ordinary times, the blinking frequency of eyes is reduced, the secretion of tears is correspondingly reduced, and meanwhile, a blinking screen strongly stimulates eyes. Eye fatigue can also cause and aggravate various eye diseases.
With the development of society, asthenopia symptoms increasingly appear in young 'games' and 'offices' and 'vehicles'. Currently, the current practice is. Although the traditional medical treatment for the asthenopia can have a certain curative effect, the side effect is obvious, for example, refractive correction is easy to relapse, the surgical treatment has a large risk, and the medical treatment is often used for temporarily relieving symptoms. Therefore, on the basis of the principle of "prevention is the main and the first", in recent years, the prevention or alleviation of asthenopia by a diet therapy method has become a hot point.
Disclosure of Invention
Aiming at the technical problems of the existing visual fatigue relieving, the invention provides a composition with the visual fatigue relieving function, a health food and a preparation method thereof.
In order to achieve the purpose of the invention, the embodiment of the invention adopts the following technical scheme:
the composition with the function of relieving visual fatigue comprises the following components in parts by weight: 5-40 parts of blueberry powder; 0.2-15 parts of cowberry concentrated powder; 0.1-10 parts of lutein; 0.1-10 parts of grape seed extract; 0.1-10 parts of vitamin mineral premix.
Further, the composition with the function of relieving visual fatigue comprises the following components in parts by weight: 15-35 parts of blueberry powder; 1-10 parts of cowberry concentrated powder; 1-5 parts of lutein; 0.2-5 parts of grape seed extract; 0.2-5 parts of vitamin mineral premix.
Further, the composition with the function of relieving visual fatigue comprises the following components in parts by weight: 28 parts of blueberry powder; 3 parts of cowberry fruit concentrated powder; 2 parts of lutein; 2 parts of grape seed extract; 1 part of vitamin mineral premix.
Further, the vitamin mineral premix comprises the following components in parts by weight: 4.0-5.5 mg/g of vitamin A acetate; vitamin B650-75 mg/g; 0.3-0.5 mg/g of sodium selenite; 75-100 mg/g of zinc gluconate and maltodextrin as a carrier. The vitamins and the zinc and selenium elements have synergistic effect, can effectively delay the visual deterioration, and are beneficial to improving the vision and relieving the visual fatigue.
The blueberry powder is prepared by using blueberries as raw materials, and crushing freeze-dried powder by adopting a vacuum freeze-drying technology and a low-temperature physical crushing technology. The blueberry powder is rich in various amino acids, vitamins and trace elements, also contains rich anthocyanin, has super-strong antioxidant activity and free radical scavenging capacity, has an obvious protective effect on oxidative damage of cells, can promote blood circulation around eyes, effectively activates retina and relieves asthenopia.
The cowberry fruit concentrated powder contains abundant substances beneficial to human health, such as vitamin C, vitamin E, vitamin A, tannic acid, folic acid, procyanidin, anthocyanin, etc. The proanthocyanidins and the anthocyanins are 25-40% by mass and 10-20% by mass, have the effects of maintaining the integrity of capillary vessels and stabilizing collagen, and are used together with the blueberry powder to strengthen the capillary vessels in eyes, promote blood circulation, improve the tension strength and integrity of eye tissues and protect the eyes from being damaged by free radicals.
The lutein is dihydroxy carotenoid cord containing ionone ring, and can prevent retina injury caused by blue light, promote rhodopsin regeneration and relieve asthenopia. Meanwhile, the lutein has strong oxidation resistance and free radical scavenging capacity, has a remarkable protection effect on vision loss caused by retinal color spot fading under the combined action of the lutein and anthocyanin in the blueberry powder and the cowberry concentrated powder, and delays the aging of eyes.
The grape seed extract is obtained by solvent extraction, microwave extraction, ultrasonic extraction or supercritical CO extraction2The polyphenol substances extracted and separated from grape seeds by the extraction method contain a large amount of procyanidine, the mass content of the procyanidine is 95-98%, the polyphenol substances and the vitamin mineral premix are used together to promote the metabolism of a human body and improve the immunity of the human body, and meanwhile, the polyphenol substances are synergistic with blueberry powder, cowberry fruit concentrated powder and lutein to further improve the effect of relieving visual fatigue of the composition.
The vitamins and minerals in the vitamin mineral premix can promote metabolism of a human body, delay visual deterioration and help to relieve eye inflammation and visual fatigue, and the vitamin mineral premix and other components act together to overcome the problem of relative limitation of action sites of single nutrient for relieving visual fatigue and improve the efficacy of the composition for relieving visual fatigue.
Compared with the prior art, the composition with the function of relieving the asthenopia provided by the invention has the advantages that the blueberry powder, the blueberry concentrated powder, the grape seed extract, the lutein and the vitamin mineral premix are compatible, so that the active substances such as procyanidine, anthocyanin, lutein, vitamin and mineral substances are subjected to synergistic action, the blood circulation of eyes is promoted, the regeneration of rhodopsin is promoted, the retinal damage caused by blue light is prevented, the eyes are protected from being damaged by free radicals, the retinal color spots are slowed down, and the like, the action sites for relieving the asthenopia are increased, the aim of relieving the asthenopia can be achieved through the combined action of multiple ways, and the obtained composition has a good effect of relieving the asthenopia.
The invention also provides a health food with the function of relieving visual fatigue, which comprises the composition with the function of relieving visual fatigue. The health food with asthenopia relieving function is in the form of granule, powder or tablet.
The invention also provides granules with the function of relieving visual fatigue, which comprise the composition with the function of relieving visual fatigue and 10-40 parts of maltodextrin; 5-40 parts of xylitol; 0.1-0.2 part of sucralose and 0.2-5 parts of citric acid.
Further, 15-35 parts of maltodextrin; 10-35 parts of xylitol; 0.1-0.15 part of sucralose and 0.2-2 parts of citric acid.
The invention also provides a preparation method of the granules with the function of relieving asthenopia, which comprises the following steps:
mixing the composition with the maltodextrin, the xylitol, the sucralose and the citric acid, and preparing the granules according to a conventional method.
The preparation method of the granules with the function of relieving the asthenopia, provided by the invention, has the advantages of simple process, safety and reliability, and no other additives are added in the process, so that the active ingredients in the composition are effectively reserved, and the obtained granules have a good effect of relieving the asthenopia.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1
The composition with the function of relieving visual fatigue comprises the following components in parts by weight: 28 parts of blueberry powder; 3 parts of cowberry fruit concentrated powder; 2 parts of lutein; 2 parts of grape seed extract; 1 part of vitamin mineral premix, wherein the vitamin mineral premix comprises the following components: 5.0mg/g of vitamin A acetate; vitamin B665 mg/g; sodium selenite 0.4 mg/g; 90mg/g of zinc gluconate, and the balance of maltodextrin as a carrier.
The granules with the function of relieving visual fatigue comprise the composition with the function of relieving visual fatigue and 30 parts of maltodextrin; 30 parts of xylitol; 0.1 part of sucralose and 1 part of citric acid.
The preparation method of the granules with the function of relieving visual fatigue comprises the following steps:
mixing the above composition with maltodextrin, xylitol, sucralose and citric acid, and making into granule by conventional method.
Example 2
The composition with the function of relieving visual fatigue comprises the following components in parts by weight: 15 parts of blueberry powder; 10 parts of cowberry fruit concentrated powder; 1 part of lutein; 0.2 part of grape seed extract; 5 parts of vitamin mineral premix, wherein the vitamin mineral premix comprises the following components: vitamin A acetate 4.0 mg/g; vitamin B675 mg/g; sodium selenite 0.3 mg/g; 100mg/g of zinc gluconate, and the balance of maltodextrin as a carrier.
The powder with the function of relieving the asthenopia comprises the composition with the function of relieving the asthenopia and 15 parts of maltodextrin; 35 parts of xylitol; 0.1 part of sucralose and 2 parts of citric acid.
The preparation method of the powder with the function of relieving the asthenopia comprises the following steps:
mixing the above composition with maltodextrin, xylitol, sucralose and citric acid, and making into powder by conventional method.
Example 3
The composition with the function of relieving visual fatigue comprises the following components in parts by weight: 35 parts of blueberry powder; 1 part of cowberry concentrated powder; 5 parts of lutein; 5 parts of grape seed extract; 0.2 part of vitamin mineral premix, wherein the vitamin mineral premix comprises the following components: 5.5mg/g of vitamin A acetate; vitamin B650 mg/g; sodium selenite 0.5 mg/g; 75mg/g of zinc gluconate, and the balance of maltodextrin.
The granules with the function of relieving visual fatigue comprise the composition with the function of relieving visual fatigue and 35 parts of maltodextrin; 10 parts of xylitol; 0.15 part of sucralose and 0.2 part of citric acid.
The preparation method of the granules with the function of relieving visual fatigue comprises the following steps:
mixing the above composition with maltodextrin, xylitol, sucralose and citric acid, and making into granule by conventional method.
Example 4
The composition with the function of relieving visual fatigue comprises the following components in parts by weight: 5 parts of blueberry powder; 15 parts of cowberry fruit concentrated powder; 10 parts of lutein; 10 parts of grape seed extract; 0.1 part of vitamin and mineral premix, wherein the vitamin and mineral premix comprises the following components: vitamin A acetate 4.0 mg/g; vitamin B655 mg/g; sodium selenite 0.5 mg/g; 80mg/g of zinc gluconate, and the balance of maltodextrin.
The tablet with the function of relieving the asthenopia comprises the composition with the function of relieving the asthenopia and 10 parts of maltodextrin; 40 parts of xylitol; 0.1 part of sucralose and 5 parts of citric acid.
The preparation method of the tablet with the function of relieving the asthenopia comprises the following steps:
mixing the above composition with maltodextrin, xylitol, sucralose and citric acid, and making into tablet by conventional method.
Example 5
The composition with the function of relieving visual fatigue comprises the following components in parts by weight: 40 parts of blueberry powder; 0.2 part of cowberry concentrated powder; 0.1 part of lutein; 0.1 part of grape seed extract; 10 parts of vitamin mineral premix, wherein the vitamin mineral premix comprises the following components: 5.5mg/g of vitamin A acetate; vitamin B650 mg/g; sodium selenite 0.3 mg/g; 78mg/g of zinc gluconate and the balance of maltodextrin.
The granules with the function of relieving visual fatigue comprise the composition with the function of relieving visual fatigue and 40 parts of maltodextrin; 5 parts of xylitol; 0.2 part of sucralose and 0.2 part of citric acid.
The preparation method of the granules with the function of relieving visual fatigue comprises the following steps:
mixing the above composition with maltodextrin, xylitol, sucralose and citric acid, and making into granule by conventional method.
In order to better illustrate the characteristics of the composition with asthenopia relieving function and the corresponding health food provided by the embodiment of the invention, the granules prepared in example 1 are clinically tested.
1. Human body test eating experiment:
1.1 sample
The granules of the embodiment 1 of the invention are taken by a test group, the specification is 5 g/bag, and the recommended amount for human body is 1 time per day and 1 bag per time for each person (55-65 kg adult).
1.2 test subjects
The subjects 18-65 years old with asthenopia symptoms were selected on a voluntary basis.
Inclusion criteria: the fatigue of vision is easy for people to use eyes for a long time.
Exclusitor criteria: patients with infectious, traumatic eye disease; eye surgery is performed for less than 3 months; patients with internal and external eye diseases such as cornea, lens, vitreous body, fundus oculi lesion, etc.; patients with cardiovascular, cerebrovascular, hepatic, renal, and hematopoietic diseases; pregnant or lactating women, allergic constitution patients; taking articles related to the tested function in a short time to influence the result judger; the patients who take the medicaments, health products or other treatment methods related to the vision treatment for a long time cannot be stopped; if the test substance does not meet the inclusion standard, the test substance is not eaten according to the regulation, or the data is not complete, which affects the efficacy or safety judgment.
1.3 test methods
Grouping according to random and double-blind requirements, and balancing the symptoms and vision level of the trial group and the control group according to the symptoms and vision examination conditions during grouping. Meanwhile, factors such as age, sex and the like are considered, so that the two groups have comparability. The number of the test subjects in each group is not less than 50 at the end of the feeding trial. The test group takes the test sample 1 time a day with 1 bag each time according to the recommended taking method and dosage. The control group received placebo. The subject is administered for 60 consecutive days. The subject stopped taking medications or other health care products related to improving vision during the feeding period. The test and control groups are subjected to safety observation (blood, urine and feces routine, biochemical index mapping and the like) and efficacy observation (symptom inquiry, eye condition, ophthalmic examination and photopic vision persistence detection).
The photopic vision persistence determination method comprises the following steps: a three-dimensional block diagram in a shape like a Chinese character pin is drawn on an inspection table, each side of a square block is 1 cm, and the local illumination is 100-150 LX (a specially manufactured lamp box can be used). The distance between the checklist and the eyes should be kept at a proper distance according to the visual habit of the subject, and the subject is defined to see the image of the character "Pin" as photopic vision, and to see the character "Pin" as non-photopic vision, and the measurement time is 3 minutes.
Photopic vision persistence ═ (photopic vision time/total fixation time) × 100%.
1.4 efficacy index
a. Effective rate for improving symptoms
The symptoms of the eye are 3 improved symptoms of ache of the eye, eye swelling, photophobia, blurred vision, dry eyes, foreign body sensation, lacrimation and general discomfort, and the symptoms are judged to be improved if other symptoms are not worsened. Two groups of symptom improvement cases and two groups of symptom improvement effective rates are calculated. The effective rate (%) for symptom improvement was calculated as the number of symptom improvement cases/number of test food cases × 100. The two groups of symptoms are tested for improving the effective rate statistically.
b. Mean integral of symptoms
The symptom scores before and after the test feeding of each test taker were calculated, the average score of the two groups was calculated, and statistical tests were performed, and the visual fatigue symptom determination method is shown in table 1.
TABLE 1
Figure BDA0002353321180000081
Note: "idopathic" means 1-2 times/2 days: sometimes "means 1-3 times per day: "often" means > 3 times per day
c. Rate of improvement of vision
After the test food is eaten, the two behaviors are improved compared with the pre-eating condition, and the vision improvement rate of two groups of patients is counted as a reference index. The reference index does not serve as a criterion for determining whether the asthenopia-relieving function is effective.
d. Persistence of photopic vision
Compared with the test group or the test group and the control group, the photopic vision persistence difference is significant (P is less than 0.05), and the improvement of the average photopic vision persistence is more than or equal to 10 percent, which is effective.
The effective rate of improving symptoms or the difference of total score of symptoms is significant (P is less than 0.05) when the test group compares with the control group; compared with the test group or the test group and the control group, the difference of the photopic vision persistence has significance (P is less than 0.05), the average photopic vision persistence is improved by more than or equal to 10 percent, the vision improvement rate is not obviously reduced, and the test object can be judged to have the function of helping to relieve the asthenopia.
1.5 results
The general data comparison was performed for the test and control groups. The subjects were included in 110 cases and were randomly divided into a test diet group and a control group. The patients who are deprived of food have 2 cases of a test group, 2 cases of a control group, 106 effective subjects, 53 cases of the test group and 53 cases of the control group, the examinations of blood routine, urine routine, stool routine, liver and kidney functions, chest X-ray, electrocardiogram, abdominal B-ultrasound and the like of the subjects before the test are all in a normal range, the grouping conditions are shown in table 2, and the ages, sexes, photopic persistence, vision, total symptom scores and eye time of the two groups of subjects before the test are not obviously different (P is more than 0.05), so that the subjects have comparability. The predator has no obvious changes in spirit, sleep, diet, defecation and the like before and after the predator takes the test.
TABLE 2
Item Test food group Control group
Number of examples 53 53
Sex (male/female) 17/36 16/37
Age (year) 57.89±5.71 57.02±9.19
Persistence of photopic vision (%) 55.2±7.3 57.7±7.1
Eyesight of left eye 5.01±0.14 5.03±0.15
Eyesight of right eye 5.04±0.13 5.05±0.15
Total score of symptoms 14.87±2.18 14.77±2.20
Eye time (h) 4.28±1.23 4.60±1.17
The results of the tests on the blood routine, the urine routine, the stool routine and the blood biochemical indexes of the test group and the control group before and after the test are shown in table 3, the blood routine and the blood biochemical indexes of two groups of subjects are basically in a normal range, and the blood routine and the blood biochemical indexes of the two groups of subjects have no significant change (P is more than 0.05) before and after the test. The routine urine and routine stool are normal before and after the two groups of test meals. In addition, before eating trial, the food trial group and the control group have chest X-ray, electrocardiogram and abdomen B-ultrasound within normal range, and have no adverse reaction and anaphylactic reaction after eating trial.
TABLE 3
Figure BDA0002353321180000101
The change in the score of symptoms before and after the test is shown in table 4, and the improvement in the chief complaints after the test is shown in table 5.
TABLE 4
Grouping Before tasting After eating trial
Test food group 14.87±2.18 13.36±2.99***#
Control group 14.77±2.20 14.45±2.48
P <0.001 by self; comparison between group # p <0.05
TABLE 5
Figure BDA0002353321180000111
Test group data (control group data)
The change of photopic vision duration is shown in table 6, and the effective rate results of symptom improvement are shown in table 7.
TABLE 6
Grouping Predate (%) After tasting (%) Increase value (%)
Test food group 55.2±7.3 65.3±7.1***### 10.1±6.6###
Control group 57.7±7.1 59.3±6.9 1.6±6.6
P <0.001 by self; comparison between groups # p <0.001
TABLE 7
Grouping Number of examples Is effective Invalidation The total effective rate%
Test food group 53 22 31 41.5###
Control group 53 0 53 0
Comparison between groups # p <0.001
The data show that the total integral of the comparative symptoms before and after the test feeding of the test feeding group is obviously improved (P is less than 0.001); the total symptom score is obviously improved compared with a control group after the test feeding of the test feeding group (P is less than 0.05); the total symptoms after the test feeding are 22 cases, the total effective rate is 41.5 percent, and the obvious difference (P is less than 0.001) is realized compared with a control group; compared with a control group before and after the test feeding, the photopic vision persistence degree is improved and has obvious difference (P is less than 0.001), and the average photopic vision persistence degree after the test feeding of the test feeding group is improved by 10.1 percent and has obvious difference (P is less than 0.001) higher than that of the control group. According to the judgment standard of the function of relieving the asthenopia in the national food and drug administration of the State food and drug administration of [2012]107 annex 4, the result shows that the granules provided by the embodiment of the invention have the function of relieving the asthenopia. The health food provided in embodiments 2 to 5 of the present invention has an effect equivalent to that of the granules in embodiment 1.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents or improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.

Claims (8)

1. The composition with the function of relieving visual fatigue is characterized by comprising the following components in parts by weight: 5-40 parts of blueberry powder; 0.2-15 parts of cowberry concentrated powder; 0.1-10 parts of lutein; 0.1-10 parts of grape seed extract; 0.1-10 parts of vitamin mineral premix.
2. The composition with the function of relieving the asthenopia as claimed in claim 1, which is characterized by comprising the following components in parts by weight: 15-35 parts of blueberry powder; 1-10 parts of cowberry concentrated powder; 1-5 parts of lutein; 0.2-5 parts of grape seed extract; 0.2-5 parts of vitamin mineral premix.
3. The composition with the function of relieving the asthenopia as claimed in claim 1, which is characterized by comprising the following components in parts by weight: 28 parts of blueberry powder; 3 parts of cowberry fruit concentrated powder; 2 parts of lutein; 2 parts of grape seed extract; 1 part of vitamin mineral premix.
4. The composition with asthenopia relieving function according to any one of claims 1 to 3, wherein: the vitamin mineral premix comprises the following components in parts by weight: 4.0-5.5 mg/g of vitamin A acetate; vitamin B650-75 mg/g; 0.3-0.5 mg/g of sodium selenite; 75-100 mg/g of zinc gluconate and maltodextrin as a carrier.
5. A health food having an asthenopia-relieving function, which comprises the composition having an asthenopia-relieving function as claimed in any one of claims 1 to 4.
6. The health food with asthenopia relieving function according to claim 5, wherein: the dosage form is granule, powder or tablet.
7. A granule with asthenopia relieving function, which is characterized by comprising the composition with asthenopia relieving function of any one of claims 1 to 4, and 10-40 parts of maltodextrin; 5-40 parts of xylitol; 0.1-0.2 part of sucralose and 0.2-5 parts of citric acid.
8. The method for preparing granules with asthenopia relieving function according to claim 7, which comprises the following steps:
mixing the composition with the maltodextrin, the xylitol, the sucralose and the citric acid, and preparing the granules according to a conventional method.
CN202010000833.3A 2020-01-02 2020-01-02 Composition with function of relieving asthenopia and preparation method thereof Pending CN113057298A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010000833.3A CN113057298A (en) 2020-01-02 2020-01-02 Composition with function of relieving asthenopia and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010000833.3A CN113057298A (en) 2020-01-02 2020-01-02 Composition with function of relieving asthenopia and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113057298A true CN113057298A (en) 2021-07-02

Family

ID=76558083

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010000833.3A Pending CN113057298A (en) 2020-01-02 2020-01-02 Composition with function of relieving asthenopia and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113057298A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104489677A (en) * 2014-12-19 2015-04-08 北京世纪合辉医药科技股份有限公司 Health food for relieving visual fatigue and preparation method thereof
CN106490619A (en) * 2016-11-17 2017-03-15 益倍（天津）生物科技有限公司 A kind of health food that alleviates asthenopia, prevent visual deterioration
CN107375504A (en) * 2017-08-15 2017-11-24 庞会心 A kind of composition for preventing and treating visual fatigue and preparation method and application
WO2018212152A1 (en) * 2017-05-15 2018-11-22 株式会社坪田ラボ Composition and functional food for preventing myopia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104489677A (en) * 2014-12-19 2015-04-08 北京世纪合辉医药科技股份有限公司 Health food for relieving visual fatigue and preparation method thereof
CN106490619A (en) * 2016-11-17 2017-03-15 益倍（天津）生物科技有限公司 A kind of health food that alleviates asthenopia, prevent visual deterioration
WO2018212152A1 (en) * 2017-05-15 2018-11-22 株式会社坪田ラボ Composition and functional food for preventing myopia
CN107375504A (en) * 2017-08-15 2017-11-24 庞会心 A kind of composition for preventing and treating visual fatigue and preparation method and application

Similar Documents

Publication Publication Date Title
ES2710750T3 (en) Composition used to improve the density of macular pigment in the eyes and prevent or treat age-related macular degeneration
US7887847B2 (en) Nutritional supplement for treatment of ocular diseases
Riva et al. The effect of a natural, standardized bilberry extract (Mirtoselect®) in dry eye: a randomized, double blinded, placebo-controlled trial.
EP2138055B1 (en) Formula food to be beneficial for visuognosis persistence and use thereof
US10647669B2 (en) Composition containing lutein/lutein ester and applications thereof
CN101703559B (en) Medicinal composition with function of relieving visual fatigue and preparation method thereof
CN102763847A (en) Health-care food with function of relieving visual fatigue and preparation method thereof
CN109619566A (en) A kind of nutraceutical for alleviating asthenopia
CN102753163A (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurenine-o-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
CN108041609B (en) Food composition with functions of relieving visual fatigue and preventing myopia and preparation method thereof
CN112715729A (en) Blueberry lutein ester tablet candy for relieving visual fatigue and preparation method thereof
CN103798808A (en) Nutrient formula and application thereof to food or medicine for reliving asthenopia
CN105520137B (en) It is a kind of that there is the health food alleviated visual fatigue and protect visual function
CN103316032B (en) Compositions containing hydroxytyrosol and application thereof
CN113826894A (en) Capsule for relieving visual fatigue and preparation method thereof
CN108902973A (en) A kind of cowberry lutein particle and preparation method thereof
CN102150860B (en) Composition for easing visual fatigue and assisting in improving memory
US20130030046A1 (en) Use of black soybean hull extracts in manufacture of products for preventing and treating osteoarthritis
CN113057298A (en) Composition with function of relieving asthenopia and preparation method thereof
CN110839887A (en) Composition with asthenopia relieving function, health food and preparation method thereof
CN101040893A (en) Blueberry capsule for protecting vision and the preparing method
CN108338364A (en) Composition for relieving asthenopia containing theanine and astaxanthin
CN1785053A (en) Health-care food for relieving-vision fatigue and its prepn. method
CN112913957A (en) Liver-protecting sargassum salina tablet candy and preparation method thereof
CN112385755A (en) A preparation method of fruit and vegetable beverage with eyesight protecting effect

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210702

RJ01 Rejection of invention patent application after publication